Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results
-
Companies with NDRs 08/12
-
Omeros (OMER) Announces Pricing of Public Offerings of Common Stock, Convertible Notes
-
Omeros Announces Pricing of Public Offerings
-
Pacific Bio (PACB) Prices 19.43M Share Common Offering at $4.47/Sh
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Bio (PACB) Announces $75M Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Fusion Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing August 14, 2020
-
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
-
Trevena (TRVN) to Offer Common Stock
-
Trevena Announces Proposed Public Offering of Common Stock
-
Despite Concerns, Cantor Fitzgerald Thinks Mesoblast's (MESO) Ryoncil Could Be Approved
-
Companies with NDRs 08/11
-
JMP Group Announces Changes in Sales and Trading Leadership
-
Tilray (TLRY) PT Lowered to $7.90 at Cantor Fitzgerald
-
Form EFFECT Cantor Fitzgerald Income
-
Form S-3D Cantor Fitzgerald Income
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
-
Cara Therapeutics Reports Second Quarter 2020 Financial Results
-
Form RW Cantor Fitzgerald Income
-
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
-
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
-
Companies with NDRs 08/10
-
UPDATE: Cantor Fitzgerald Starts GoHealth Inc. (GOCO) at Overweight
-
Form S-3 Cantor Fitzgerald Income
-
HMS Holdings (HMSY) PT Raised to $35 at Cantor Fitzgerald
-
Piper Sandler Expands Equity Capital Markets with the Hiring of Michael Kane
-
Zoetis Inc. (ZTS) PT Raised to $185 at Cantor Fitzgerald, Following Earnings
-
PolarityTE (PTE) PT Raised to $4 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Hecla Mining (HL) to Buy
-
ANI Pharmaceuticals (ANIP) PT Lowered to $30 at Cantor Fitzgerald, Following Earnings
-
Companies with NDRs 08/06
-
Spectrum Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 8-K Cantor Fitzgerald Income For: Jul 30
-
Humana (HUM) PT Raised to $425 at Cantor Fitzgerald
-
(TLC) PT Lowered to $11 at Cantor Fitzgerald, Following Earnings
-
Freddie Mac Prices $927 Million Multifamily K-Deal, K-F83
-
BGC Announcing Tender Offer For Any And All Of Its $300 Million Outstanding 5.125% Senior Notes Due 2021
-
Companies with NDRs 8/05
-
Acreage Announces Upcoming Conference Presentations
-
Ur-Energy Inc. Announces Closing of $4.68 Million Registered Direct Offering
-
E.Merge Technology Acquisition Corp. Announces Closing of $522,000,000 Initial Public Offering
-
E.Merge Technology Acquisition Corp. Announces Closing of $522,000,000 Initial Public Offering
-
Amarin (AMRN) Retaining EU Rights 'The Right Thing to Do' - Cantor Fitzgerald
-
Durect Corp (DRRX) DUR-928 Timelines Remain On-Track - Cantor Fitzgerald
